Compass Therapeutics Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 35

Employees

  • Stock Symbol
  • CMPX

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $2.41
  • (As of Thursday Closing)

Compass Therapeutics General Information

Description

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.

Contact Information

Formerly Known As
Kairos Biologics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 80 Guest Street
  • Suite 601
  • Boston, MA 02135
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 80 Guest Street
  • Suite 601
  • Boston, MA 02135
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Compass Therapeutics Stock Performance

As of 12-Jun-2025, Compass Therapeutics’s stock price is $2.41. Its current market cap is $333M with 138M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.41 $2.43 $0.77 - $4.08 $333M 138M 1.45M -$0.41

Compass Therapeutics Financials Summary

As of 31-Mar-2025, Compass Therapeutics has a trailing 12-month revenue of $850K.

In Thousands,
USD
TTM 31-Mar-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 142,649 70,979 37,219 517,360
Revenue 850 850 0 0
EBITDA (53,569) (56,075) (49,694) (39,681)
Net Income (55,223) (49,375) (42,494) (39,225)
Total Assets 131,451 140,403 156,875 199,645
Total Debt 6,381 6,634 1,733 2,935
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Compass Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Compass Therapeutics‘s full profile, request access.

Request a free trial

Compass Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics t
Drug Discovery
Boston, MA
35 As of 2024

San Diego, CA
 

Vancouver, Canada
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Compass Therapeutics Competitors (88)

One of Compass Therapeutics’s 88 competitors is AnaptysBio, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AnaptysBio Formerly VC-backed San Diego, CA
Zymeworks Formerly VC-backed Vancouver, Canada
Arcus Biosciences Formerly VC-backed Hayward, CA
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Agenus Formerly VC-backed Lexington, MA
You’re viewing 5 of 88 competitors. Get the full list »

Compass Therapeutics Patents

Compass Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220111047-A1 Formulations of antibodies that bind human cd137 and uses thereof Pending 16-Jan-2019
EP-3911679-A1 Formulations of antibodies that bind human cd137 and uses thereof Pending 16-Jan-2019
CA-3127072-A1 Formulations of antibodies that bind human cd137 and uses thereof Pending 16-Jan-2019
AU-2020208397-A1 Formulations of antibodies that bind human cd137 and uses thereof Pending 16-Jan-2019
US-20220090125-A1 Transgenic mouse expressing common human light chain Pending 21-Dec-2018 C12N15/8509
To view Compass Therapeutics’s complete patent history, request access »

Compass Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Compass Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Compass Therapeutics‘s full profile, request access.

Request a free trial

Compass Therapeutics Acquisitions (2)

Compass Therapeutics’s most recent deal was a Merger/Acquisition with TRIGR Therapeutics for . The deal was made on 25-Jun-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
TRIGR Therapeutics 25-Jun-2021 Merger/Acquisition Drug Discovery
Olivia Ventures 23-Jun-2020 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
To view Compass Therapeutics’s complete acquisitions history, request access »

Compass Therapeutics ESG

Risk Overview

Risk Rating

Updated February, 22, 2024

33.89 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,673

Rank

Percentile

Pharmaceuticals

Industry

of 844

Rank

Percentile

Pharmaceuticals

Subindustry

of 419

Rank

Percentile

To view Compass Therapeutics’s complete esg history, request access »

Compass Therapeutics Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
TRIGR Therapeutics Irvine, CA 2018

Compass Therapeutics FAQs

  • When was Compass Therapeutics founded?

    Compass Therapeutics was founded in 2014.

  • Where is Compass Therapeutics headquartered?

    Compass Therapeutics is headquartered in Boston, MA.

  • What is the size of Compass Therapeutics?

    Compass Therapeutics has 35 total employees.

  • What industry is Compass Therapeutics in?

    Compass Therapeutics’s primary industry is Drug Discovery.

  • Is Compass Therapeutics a private or public company?

    Compass Therapeutics is a Public company.

  • What is Compass Therapeutics’s stock symbol?

    The ticker symbol for Compass Therapeutics is CMPX.

  • What is the current stock price of Compass Therapeutics?

    As of 12-Jun-2025 the stock price of Compass Therapeutics is $2.41.

  • What is the current market cap of Compass Therapeutics?

    The current market capitalization of Compass Therapeutics is $333M.

  • What is Compass Therapeutics’s current revenue?

    The trailing twelve month revenue for Compass Therapeutics is $850K.

  • Who are Compass Therapeutics’s competitors?

    AnaptysBio, Zymeworks, Arcus Biosciences, CytomX Therapeutics, and Agenus are some of the 88 competitors of Compass Therapeutics.

  • What is Compass Therapeutics’s annual earnings per share (EPS)?

    Compass Therapeutics’s EPS for 12 months was -$0.41.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »